Mitogen-activated protein kinase kinase kinase 8 (MAP3K8) (TPL2)

Tumor Progression Locus 2 (TPL2), also known as MAP3K8 or COT, is a serine/threonine protein kinase that functions as a critical signal transducer in the mitogen-activated protein kinase (MAPK) pathway [1, 4]. It is primarily activated by inflammatory stimuli, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and various Toll-like receptor (TLR) ligands, leading to the downstream activation of the MEK-ERK signaling cascade [2, 5]. TPL2 is essential for the production of key pro-inflammatory cytokines, making it a significant therapeutic target for chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease [4, 17]. In oncology, TPL2 often acts as an oncogene by promoting cell proliferation and survival in cancers like melanoma and pancreatic ductal adenocarcinoma, though it can paradoxically exhibit tumor-suppressive properties in certain contexts [3, 8, 11]. Current drug development efforts focus on small-molecule inhibitors, such as tilpisertib, which aim to modulate immune responses and inhibit tumor progression by selectively blocking TPL2 kinase activity [14, 18].

Other names

COTCancer Osaka thyroidMAP3K8TPL-2ESTESTFProto-oncogene c-Cot

Kinase inhibition; specifically, it selectively blocks the catalytic activity of TPL2, thereby disrupting the downstream MEK-ERK signaling cascade and reducing the production of pro-inflammatory cytokines such as TNF-alpha and IL-1beta.